NEWS

November 16, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2022
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
November 9, 2022
Travere Therapeutics to Present at Upcoming Investor Conferences
October 27, 2022
Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 26, 2022
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
October 20, 2022
Travere Therapeutics to Report Third Quarter 2022 Financial Results
October 13, 2022
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
October 13, 2022
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
October 11, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 23, 2022
Travere Wins PM360 Trailblazer Specialty Pharma/Biotech Company of the Year Award for its Work in Rare Disease
September 14, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 6, 2022
Jula Inrig Named to PharmaVoice 100 Top Industry Leaders List for 2022